PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab
Haiyong Wang, Qinge Shan, Jun Guo, Xiao Han, Chenglong Zhao, Huijuan Li, Zhehai Wang
Topics & Concepts
AtezolizumabMedicineOncologySTK11Internal medicineMutationPopulationSurvival analysisGene mutationGeneLogistic regressionBiomarkerCancerCancer researchImmunotherapyPembrolizumabGeneticsBiologyKRASEnvironmental healthColorectal cancerCancer Immunotherapy and BiomarkersNF-κB Signaling PathwaysLung Cancer Treatments and Mutations